{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:37:20Z","timestamp":1791405440604,"version":"4.3.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI060549"],"award-info":[{"award-number":["AI060549"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI153524"],"award-info":[{"award-number":["AI153524"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI071634"],"award-info":[{"award-number":["AI071634"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI060549"],"award-info":[{"award-number":["AI060549"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"UTMB Technology Commercialization Program"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A plague vaccine with a fusion cassette of <jats:underline>Y<\/jats:underline>scF, <jats:underline>F<\/jats:underline>1, and Lcr<jats:underline>V<\/jats:underline> encoding genes in an adenovirus-5 vector (rAd5-YFV) is evaluated for efficacy and immune responses in mice. Two doses of the vaccine provides 100% protection when administered intranasally against challenge with <jats:italic>Yersinia pestis<\/jats:italic> CO92 or its isogenic F1 mutant in short- or long- term immunization in pneumonic\/bubonic plague models. The corresponding protection rates drop in rAd5-LcrV monovalent vaccinated mice in plague models. The rAd5-YFV vaccine induces superior humoral, mucosal and cell-mediated immunity, with clearance of the pathogen. Immunization of mice with rAd5-YFV followed by CO92 infection dampens proinflammatory cytokines and neutrophil chemoattractant production, while increasing Th1- and Th2-cytokine responses as well as macrophage\/monocyte chemo-attractants when compared to the challenge control animals. This is a first study showing complete protection of mice from pneumonic\/bubonic plague with a viral vector-based vaccine without the use of needles and the adjuvant.<\/jats:p>","DOI":"10.1038\/s41541-020-00275-3","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T11:18:42Z","timestamp":1611919122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform"],"prefix":"10.1038","volume":"6","author":[{"given":"Paul B.","family":"Kilgore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jourdan A.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir L.","family":"Motin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok K.","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"275_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0025802420908483","volume":"60","author":"RW Byard","year":"2020","unstructured":"Byard, R. W. A forensic evaluation of plague\u2014a re-emerging infectious disease with biowarfare potential. Med. Sci. Law 60, 200\u2013205 (2020).","journal-title":"Med. Sci. Law"},{"key":"275_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198067","volume":"13","author":"L Shi","year":"2018","unstructured":"Shi, L. et al. Reemergence of human plague in Yunnan, China in 2016. PLoS ONE 13, e0198067 (2018).","journal-title":"PLoS ONE"},{"key":"275_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1128\/CMR.10.1.35","volume":"10","author":"RD Perry","year":"1997","unstructured":"Perry, R. D. & Fetherston, J. D. Yersinia pestis\u2014\u0113tiologic agent of plague. Clin. Microbiol. Rev. 10, 35\u201366 (1997).","journal-title":"Clin. Microbiol. Rev."},{"key":"275_CR4","unstructured":"WHO (Regional Office for Africa). Plague outbreak situation reports. https:\/\/www.afro.who.int\/health-topics\/plague\/plague-outbreak-situation-reports (2017)."},{"key":"275_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1473-3099(18)30730-8","volume":"19","author":"R Randremanana","year":"2019","unstructured":"Randremanana, R. et al. Epidemiological characteristics of an urban plague epidemic in Madagascar, August\u2013November, 2017: an outbreak report. Lancet Infect. Dis. 19, 537\u2013545 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"275_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.tim.2015.11.008","volume":"24","author":"RD Pechous","year":"2016","unstructured":"Pechous, R. D., Sivaraman, V., Stasulli, N. M. & Goldman, W. E. Pneumonic plague: the darker side of Yersinia pestis. Trends Microbiol. 24, 190\u2013197 (2016).","journal-title":"Trends Microbiol."},{"key":"275_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0008251","volume":"14","author":"X Vall\u00e8s","year":"2020","unstructured":"Vall\u00e8s, X. et al. Human plague: an old scourge that needs new answers. PLoS Negl. Trop. Dis. 14, 1\u201322 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"275_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1586\/14760584.7.2.209","volume":"7","author":"ST Smiley","year":"2008","unstructured":"Smiley, S. T. Current challenges in the development of vaccines for pneumonic plague. Expert Rev. Vaccines 7, 209\u2013221 (2008).","journal-title":"Expert Rev. Vaccines"},{"key":"275_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.micinf.2019.06.007","volume":"21","author":"C Demeure","year":"2019","unstructured":"Demeure, C. et al. Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination and diagnostics. Microbes Infect. 21, 202\u2013212 (2019).","journal-title":"Microbes Infect."},{"key":"275_CR10","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1016\/j.vaccine.2007.01.071","volume":"25","author":"SR Morris","year":"2007","unstructured":"Morris, S. R. Development of a recombinant vaccine against aerosolized plague. Vaccine 25, 3115\u20133117 (2007).","journal-title":"Vaccine"},{"key":"275_CR11","first-page":"261","volume":"8","author":"AC Fasciano","year":"2019","unstructured":"Fasciano, A. C., Shaban, L. & Mecsas, J. Promises and challenges of the type three secretion system injectisome as an antivirulence target. EcoSal 8, 261\u2013276 (2019).","journal-title":"EcoSal"},{"key":"275_CR12","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1128\/CVI.00290-15","volume":"22","author":"P Fellows","year":"2015","unstructured":"Fellows, P. et al. Characterization of a cynomolgus macaque model of pneumonic plague for evaluation of vaccine efficacy. Clin. Vaccine Immunol. 22, 1070\u20131078 (2015).","journal-title":"Clin. Vaccine Immunol."},{"key":"275_CR13","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1016\/j.vaccine.2017.09.070","volume":"35","author":"SE Frey","year":"2017","unstructured":"Frey, S. E. et al. A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin\/F1\/V, in healthy adult volunteers (DMID 08-0066). Vaccine 35, 6759\u20136765 (2017).","journal-title":"Vaccine"},{"key":"275_CR14","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1080\/21645515.2016.1175261","volume":"12","author":"K Chu","year":"2016","unstructured":"Chu, K. et al. Immunogenicity and safety of subunit plague vaccine: a randomized phase 2a clinical trial. Hum. Vaccines Immunother. 12, 2334\u20132340 (2016).","journal-title":"Hum. Vaccines Immunother."},{"key":"275_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00253-011-3380-6","volume":"91","author":"JA Rosenzweig","year":"2011","unstructured":"Rosenzweig, J. A. et al. Progress on plague vaccine development. Appl. Microbiol. Biotechnol. 91, 265\u2013286 (2011).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"275_CR16","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/0264-410X(95)00090-N","volume":"13","author":"P Russell","year":"1995","unstructured":"Russell, P. et al. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13, 1551\u20131556 (1995).","journal-title":"Vaccine"},{"key":"275_CR17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/infdis\/jis433","volume":"206","author":"LE Quenee","year":"2012","unstructured":"Quenee, L. E. et al. Hereditary hemochromatosis restores the virulence of plague vaccine strains. J. Infect. Dis. 206, 1050\u20131058 (2012).","journal-title":"J. Infect. Dis."},{"key":"275_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/0-306-48416-1_76","volume":"529","author":"TV Meka-Mechenko","year":"2003","unstructured":"Meka-Mechenko, T. V. F1-negative natural Y. pestis Strains. Adv. Exp. Med. Biol. 529, 379\u2013381 (2003).","journal-title":"Adv. Exp. Med. Biol"},{"key":"275_CR19","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1128\/JCM.00064-11","volume":"49","author":"J Sha","year":"2011","unstructured":"Sha, J. et al. Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks. J. Clin. Microbiol. 49, 1708\u20131715 (2011).","journal-title":"J. Clin. Microbiol."},{"key":"275_CR20","doi-asserted-by":"crossref","unstructured":"Daniel, C. et al. Polymorphism in the yersinia LcrV antigen enables immune escape from the protection conferred by an LcrV-secreting Lactococcus lactis in a pseudotuberculosis mouse model. Front. Immunol. 10, 1830 (2019).","DOI":"10.3389\/fimmu.2019.01830"},{"key":"275_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0105-9","volume":"4","author":"W Sun","year":"2019","unstructured":"Sun, W. & Singh, A. K. Plague vaccine: recent progress and prospects. npj Vaccines 4, 11 (2019).","journal-title":"npj Vaccines"},{"key":"275_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1146\/annurev-micro-090817-062436","volume":"73","author":"KI Bos","year":"2019","unstructured":"Bos, K. I. et al. Paleomicrobiology: diagnosis and evolution of ancient pathogens. Annu. Rev. Microbiol. 73, 639\u2013666 (2019).","journal-title":"Annu. Rev. Microbiol."},{"key":"275_CR23","doi-asserted-by":"publisher","first-page":"14043","DOI":"10.1073\/pnas.96.24.14043","volume":"96","author":"M Achtman","year":"1999","unstructured":"Achtman, M. et al. Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis. Proc. Natl Acad. Sci. USA 96, 14043\u201314048 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"275_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1128\/CVI.00150-16","volume":"23","author":"J Sha","year":"2016","unstructured":"Sha, J. et al. A Replication-Defective Human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates. Clin. Vaccine Immunol. 23, 586\u2013600 (2016).","journal-title":"Clin. Vaccine Immunol."},{"key":"275_CR25","unstructured":"WHO Workshop. Efficacy trials of Plague vaccines: endpoints, trial design, site selection. https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjUqsSx7p7uAhUHTawKHaMQBzUQFjAAegQIAhAC&url=https%3A%2F%2Fwww.who.int%2Fblueprint%2Fwhat%2Fnormsstandards%2FPlagueVxeval_FinalMeetingReport.pdf&usg=AOvVaw2nPIcR6FgJA9HLKUnQgXUp (2018)."},{"key":"275_CR26","doi-asserted-by":"publisher","first-page":"16020","DOI":"10.1038\/npjvaccines.2016.20","volume":"1","author":"BL Tiner","year":"2016","unstructured":"Tiner, B. L. et al. Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague. npj Vaccines 1, 16020 (2016).","journal-title":"npj Vaccines"},{"key":"275_CR27","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/hum.2009.148","volume":"21","author":"JL Boyer","year":"2010","unstructured":"Boyer, J. L. et al. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Hum. Gene Ther. 21, 891\u2013901 (2010).","journal-title":"Hum. Gene Ther."},{"key":"275_CR28","doi-asserted-by":"publisher","first-page":"9590","DOI":"10.1128\/JVI.00740-12","volume":"86","author":"JE Teigler","year":"2012","unstructured":"Teigler, J. E., Iampietro, M. J. & Barouch, D. H. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in Rhesus monkeys. J. Virol. 86, 9590\u20139598 (2012).","journal-title":"J. Virol."},{"key":"275_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2018.1486154","volume":"14","author":"J Hu","year":"2018","unstructured":"Hu, J. et al. One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: an extended open-label study. Hum. Vaccine Immunother. 14, 1\u20135 (2018).","journal-title":"Hum. Vaccine Immunother."},{"key":"275_CR30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/S0264-410X(98)80110-2","volume":"16","author":"DG Heath","year":"1998","unstructured":"Heath, D. G. et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16, 1131\u20131137 (1998).","journal-title":"Vaccine"},{"key":"275_CR31","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1016\/j.vaccine.2011.04.084","volume":"29","author":"ED Williamson","year":"2011","unstructured":"Williamson, E. D. et al. Recombinant (F1 + V) vaccine protects cynomolgus macaques against pneumonic plague. Vaccine 29, 4771\u20134777 (2011).","journal-title":"Vaccine"},{"key":"275_CR32","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1128\/IAI.70.3.1453-1460.2002","volume":"70","author":"Y Du","year":"2002","unstructured":"Du, Y., Rosqvist, R. & Forsberg, \u00c5. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect. Immun. 70, 1453\u20131460 (2002).","journal-title":"Infect. Immun."},{"key":"275_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cbi.2016.03.030","volume":"267","author":"CE Demeure","year":"2017","unstructured":"Demeure, C. E., Derbise, A. & Carniel, E. Oral vaccination against plague using Yersinia pseudotuberculosis. Chem. Biol. Interact. 267, 89\u201395 (2017).","journal-title":"Chem. Biol. Interact."},{"key":"275_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2180-5-38","volume":"5","author":"JS Matson","year":"2005","unstructured":"Matson, J. S., Durick, K. A., Bradley, D. S. & Nilles, M. L. Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC Microbiol. 5, 38 (2005).","journal-title":"BMC Microbiol"},{"key":"275_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.pep.2005.02.016","volume":"42","author":"W Swietnicki","year":"2005","unstructured":"Swietnicki, W., Powell, B. S. & Goodin, J. Yersinia pestis Yop secretion protein F: purification, characterization, and protective efficacy against bubonic plague. Protein Expr. Purif. 42, 166\u2013172 (2005).","journal-title":"Protein Expr. Purif."},{"key":"275_CR36","doi-asserted-by":"publisher","first-page":"e00296","DOI":"10.1128\/IAI.00296-19","volume":"87","author":"AK Singh","year":"2019","unstructured":"Singh, A. K., Curtiss, R. & Sun, W. A recombinant attenuated Yersinia pseudotuberculosis vaccine delivering a Y. pestis YopENt138-LcrV fusion elicits broad protection against plague and yersiniosis in mice. Infect. Immun. 87, e00296\u201319 (2019).","journal-title":"Infect. Immun."},{"key":"275_CR37","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1016\/j.vaccine.2018.05.101","volume":"36","author":"KA Gregg","year":"2018","unstructured":"Gregg, K. A. et al. A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model. Vaccine 36, 4023\u20134031 (2018).","journal-title":"Vaccine"},{"key":"275_CR38","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1016\/j.vaccine.2014.07.015","volume":"32","author":"G Dinc","year":"2014","unstructured":"Dinc, G., Pennington, J. M., Yolcu, E. S., Lawrenz, M. B. & Shirwan, H. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant. Vaccine 32, 5035\u20135040 (2014).","journal-title":"Vaccine"},{"key":"275_CR39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/383787a0","volume":"383","author":"AK Abbas","year":"1996","unstructured":"Abbas, A. K., Murphy, K. M. & Sher, A. Functional diversity of helper T lymphocytes. Nature 383, 787\u2013793 (1996).","journal-title":"Nature"},{"key":"275_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jmii.2015.05.007","volume":"50","author":"M Rostamian","year":"2017","unstructured":"Rostamian, M., Sohrabi, S., Kavosifard, H. & Niknam, H. M. Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB\/c mice. J. Microbiol. Immunol. Infect. 50, 160\u2013166 (2017).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"275_CR41","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.4049\/jimmunol.1700952","volume":"199","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. IgG1 is required for optimal protection after immunization with the purified porin OmpD from Salmonella Typhimurium. J. Immunol. 199, 4103\u20134109 (2017).","journal-title":"J. Immunol."},{"key":"275_CR42","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1016\/j.vaccine.2019.07.103","volume":"37","author":"W Bowen","year":"2019","unstructured":"Bowen, W. et al. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague. Vaccine 37, 5708\u20135716 (2019).","journal-title":"Vaccine"},{"key":"275_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2020.10.101","volume":"103","author":"BK Patterson","year":"2021","unstructured":"Patterson, B. K. et al. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int. J. Infect. Dis. 103, 25\u201332 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"275_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","volume":"152","author":"S Dutta","year":"2016","unstructured":"Dutta, S. & Sengupta, P. Men and mice: relating their ages. Life Sci. 152, 244\u2013248 (2016).","journal-title":"Life Sci."},{"key":"275_CR45","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4269\/ajtmh.1998.58.793","volume":"58","author":"GW Anderson","year":"1998","unstructured":"Anderson, G. W., Heath, D. G., Bolt, C. R., Welkos, S. L. & Friedlander, A. M. Short- and long-term efficacy of single-dose sub unit vaccines against Yersinia pestis in mice. Am. J. Trop. Med. Hyg. 58, 793\u2013799 (1998).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"275_CR46","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1128\/CVI.00305-09","volume":"17","author":"Z Wang","year":"2010","unstructured":"Wang, Z. et al. Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice. Clin. Vaccine Immunol. 17, 199\u2013201 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"275_CR47","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00441-017-2753-2","volume":"371","author":"K Prame Kumar","year":"2018","unstructured":"Prame Kumar, K., Nicholls, A. J. & Wong, C. H. Y. Partners in crime: neutrophils and monocytes\/macrophages in inflammation and disease. Cell Tissue Res. 371, 551\u2013565 (2018).","journal-title":"Cell Tissue Res."},{"key":"275_CR48","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1128\/IAI.00256-10","volume":"78","author":"JE Comer","year":"2010","unstructured":"Comer, J. E. et al. Transcriptomic and innate immune responses to Yersinia pestis in the lymph node during bubonic plague. Infect. Immun. 78, 5086\u20135098 (2010).","journal-title":"Infect. Immun."},{"key":"275_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41435-019-0065-0","volume":"20","author":"CE Demeure","year":"2019","unstructured":"Demeure, C. E. et al. Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics. Genes Immun. 20, 357\u2013370 (2019).","journal-title":"Genes Immun."},{"key":"275_CR50","doi-asserted-by":"publisher","first-page":"e01530","DOI":"10.1128\/mBio.01530-15","volume":"6","author":"NM Stasulli","year":"2015","unstructured":"Stasulli, N. M. et al. Spatially distinct neutrophil responses within the inflammatory lesions of pneumonic plague. mBio 6, e01530\u201315 (2015).","journal-title":"mBio"},{"key":"275_CR51","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3389\/fimmu.2019.02759","volume":"10","author":"M Gschwandtner","year":"2019","unstructured":"Gschwandtner, M., Derler, R. & Midwood, K. S. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front. Immunol 10, 2759 (2019).","journal-title":"Front. Immunol"},{"key":"275_CR52","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/ni735","volume":"2","author":"RS Bystry","year":"2001","unstructured":"Bystry, R. S., Aluvihare, V., Welch, K. A., Kallikourdis, M. & Betz, A. G. B cells and professional APCs recruit regulatory T cells via CCL4. Nat. Immunol. 2, 1126\u20131132 (2001).","journal-title":"Nat. Immunol."},{"key":"275_CR53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/jir.2014.0149","volume":"35","author":"P Bhattacharya","year":"2015","unstructured":"Bhattacharya, P. et al. Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy. J. Interferon Cytokine Res. 35, 585\u2013599 (2015).","journal-title":"J. Interferon Cytokine Res."},{"key":"275_CR54","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev.immunol.21.120601.141040","volume":"21","author":"RM Steinman","year":"2003","unstructured":"Steinman, R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685\u2013711 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"275_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.micpath.2012.09.011","volume":"55","author":"J Sha","year":"2013","unstructured":"Sha, J. et al. A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague. Microb. Pathog. 55, 39\u201350 (2013).","journal-title":"Microb. Pathog."},{"key":"275_CR56","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1128\/IAI.02778-14","volume":"83","author":"BL Tiner","year":"2015","unstructured":"Tiner, B. L. et al. Combinational deletion of three membrane protein-encoding genes highly attenuates Yersinia pestis while retaining immunogenicity in a mouse model of pneumonic Plague. Infect. Immun. 83, 1318\u20131338 (2015).","journal-title":"Infect. Immun."},{"key":"275_CR57","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.4049\/jimmunol.137.7.2115","volume":"137","author":"C Penit","year":"1986","unstructured":"Penit, C. In vivo thymocyte maturation. BUdR labeling of cycling thymocytes and phenotypic analysis of their progeny support the single lineage model. J. Immunol 137, 2115\u20132121 (1986).","journal-title":"J. Immunol"},{"key":"275_CR58","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/(SICI)1097-0320(19971101)29:3<233::AID-CYTO6>3.0.CO;2-C","volume":"29","author":"E Endl","year":"1997","unstructured":"Endl, E., Steinbach, P., Kn\u00fcchel, R. & Hofst\u00e4dter, F. Analysis of cell cycle\u2010related Ki\u201067 and p120 expression by flow cytometric BrdUrd\u2010Hoechst\/7AAD and immunolabeling technique. Cytometry 29, 233\u2013241 (1997).","journal-title":"Cytometry"},{"key":"275_CR59","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/eji.1830200812","volume":"20","author":"B Rocha","year":"1990","unstructured":"Rocha, B. et al. Accumulation of bromodeoxyuridine-labeled cells in central and peripheral lymphoid organs: minimal estimates of prodution and turnover rates of mature lymphocytes. Eur. J. Immunol. 20, 1697\u20131708 (1990).","journal-title":"Eur. J. Immunol."},{"key":"275_CR60","doi-asserted-by":"crossref","unstructured":"van Hoecke, L., Job, E. R., Saelens, X. & Roose, K. Bronchoalveolar lavage of murine lungs to analyze inflammatory cell infiltration. J. Vis. Exp. 123, https:\/\/www.jove.com\/v\/55398\/bronchoalveolar-lavage-murine-lungs-to-analyze-inflammatory-cell (2017).","DOI":"10.3791\/55398"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00275-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00275-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00275-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T15:06:18Z","timestamp":1674918378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-020-00275-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["275"],"URL":"https:\/\/doi.org\/10.1038\/s41541-020-00275-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}